Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation

Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada. Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The company's products under development comprises NX-1207, which is in phase III trial for the treatment of enlarged prostate; NXC-4720, an antibacterial agent that is in laboratory trials for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat, and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans; and Statins, a class of commonly prescribed cholesterol lowering drugs to treat, prevent, or reduce the risk of Alzheimer's disease. It is also in the preclinical stage of developing therapeutic products for oncological indications; and has various diagnostic markers and technologies, including a patented platform for point-of-care testing.

Contact Details

Office Address

Nymox Pharmaceutical Corporation
9900 Cavendish Boulevard, Suite 306
St.-Laurent, Quebec, Canada H4M2V2
Phone: (800) 936-9669
Fax: (514) 332-2227

Executives

Founder, Chairman & Chief Exec. Officer

Dr. Paul Averback

Chief Financial Officer, Sec. and Treasurer

Mr. Roy M. Wolvin

Business Reviews for Nymox Pharmaceutical Corporation

Related Companies